Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Trials ; 14: 162, 2013 Jun 01.
Article in English | MEDLINE | ID: mdl-23725228

ABSTRACT

BACKGROUND: Drugs predominantly prescribed in general practice should ideally be tested in that setting; however, little is known about drug trials in general practice. Our aim was to describe drug trials in Norwegian general practice over the period of a decade. METHODS: The present work concerns a 10-year retrospective study of protocols submitted to the Norwegian national medicines agency (1998 to 2007) identifying all studies involving general practitioners (GPs) as clinical investigator(s). We analyzed the number of trials, drug company involvement, patients, participating doctors, payment, medications tested and main diagnostic criteria for inclusion. We also analyzed one trial in greater detail. RESULTS: Out of 2,054 clinical drug trials, 196 (9.5%) were undertaken in general practice; 93% were multinational, 96% were industry funded and 77% included patients both from general practice and specialist care. The trials were planned to be completed in the period 1998 to 2012. A total of 23,000 patients in Norway and 340,000 patients internationally were planned to be included in the 196 trials. A median of 5 GPs participated in each trial (range 1 to 402). Only 0.7% of 831 GP investigators had general practice university affiliations. Median payment for participating investigators was €1,900 (range €0 to 13,500) per patient completing the trial. A total of 30 pharmaceutical companies were involved. The drugs most commonly studied were antidiabetics (21%), obstructive airway disease medications (12%), agents acting on the renin-angiotensin system (10%), and lipid modifying agents (10%). One trial, presented in more detail, had several characteristics of a seeding or marketing trial. CONCLUSIONS: Only one in four drug trials involving general practice were solely general practice trials and almost all were industry initiated without input from academic general practice. There was a large variation in the number of patients, participating doctors, and economic compensation for trial investigators, with some investigators receiving substantial payments.


Subject(s)
Clinical Trials as Topic/methods , General Practice , Prescription Drugs/therapeutic use , Research Design , Clinical Trials as Topic/economics , Compensation and Redress , Drug Industry/economics , General Practice/economics , Humans , Income , Multicenter Studies as Topic , Norway , Patient Selection , Prescription Drugs/adverse effects , Research Support as Topic , Retrospective Studies , Sample Size , Time Factors , Treatment Outcome
2.
Ugeskr Laeger ; 167(38): 3569-73, 2005 Sep 19.
Article in Danish | MEDLINE | ID: mdl-16219183

ABSTRACT

Paracetamol (acetaminophen) has become the most widely used antipyretic and analgesic drug for children in Denmark. However, there is a wide discrepancy between the consumption of the drug and our knowledge of children's pharmacokinetics and pharmacodynamics. Dosage, therapeutic intervals and toxic potential are different for children and adults. In this review we look at the published guidelines for treating children with paracetamol and the evidence supporting them.


Subject(s)
Acetaminophen/administration & dosage , Analgesics, Non-Narcotic/administration & dosage , Acetaminophen/adverse effects , Acetaminophen/pharmacokinetics , Acetaminophen/pharmacology , Adult , Age Factors , Analgesics, Non-Narcotic/adverse effects , Analgesics, Non-Narcotic/pharmacokinetics , Analgesics, Non-Narcotic/pharmacology , Child , Dose-Response Relationship, Drug , Evidence-Based Medicine , Humans , Infant , Liver/drug effects , Practice Guidelines as Topic
SELECTION OF CITATIONS
SEARCH DETAIL
...